Table 3.
Predictors of central apneas at nighttime.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | CI | P-value | OR | CI | P-value | |
| In the whole population | ||||||
| Age | 1.04 | 1.03–1.06 | <0.001 | - | - | - |
| Male gender | 4.09 | 2.58–6.49 | <0.001 | 10.95 | 2.87–41.78 | <0.001 |
| NYHA class | 1.51 | 1.13–2.04 | 0.006 | - | - | - |
| ICM | 2.17 | 1.34–3.50 | 0.001 | - | - | - |
| Systemic hypertension | 1.80 | 1.16–2.79 | 0.009 | - | - | - |
| Hb | 1.16 | 1.02–1.32 | 0.020 | - | - | - |
| C-reactive protein | 1.23 | 1.03–1.46 | 0.020 | - | - | - |
| LVEF | 0.97 | 0.95–0.99 | <0.001 | - | - | - |
| LVMI | 1.01 | 1.00–1.01 | 0.010 | - | - | - |
| LA volume | 1.07 | 1.04–1.10 | <0.001 | 1.09 | 1.01–1.19 | 0.040 |
| Diastolic dysfunction II-III | 3.23 | 1.82–5.73 | <0.001 | - | - | - |
| Severe MR | 2.56 | 1.13–5.79 | 0.020 | - | - | - |
| TAPSE | 0.93 | 0.89–0.98 | 0.005 | - | - | - |
| sPAP | 1.05 | 1.02–1.08 | 0.001 | - | - | - |
| NT-proBNP | 1.52 | 1.29–1.80 | <0.001 | - | - | - |
| Norepinephrine | 2.31 | 1.60–3.33 | <0.001 | - | - | - |
| ICD | 1.85 | 1.06–3.22 | 0.03 | - | - | - |
| In the HFrEF population | ||||||
| Age | 1.05 | 1.03–1.07 | <0.001 | - | - | - |
| Male gender | 4.32 | 2.36–7.88 | <0.001 | 2.99 | 1.18–7.63 | 0.020 |
| BMI | 1.10 | 1.02–1.18 | 0.009 | 1.14 | 1.02–1.26 | 0.020 |
| NYHA class | 1.60 | 1.09–2.35 | 0.020 | - | - | - |
| ICM | 3.27 | 1.68–6.32 | <0.001 | - | - | - |
| Atrial fibrillation | 2.45 | 1.12–5.46 | 0.030 | - | - | - |
| Systemic hypertension | 2.29 | 1.26–4.17 | 0.007 | - | - | - |
| Creatinine | 2.65 | 1.20–5.81 | 0.020 | - | - | - |
| eGFR | 0.99 | 0.98–1.00 | 0.020 | - | - | - |
| LVEF | 0.94 | 0.90–0.98 | 0.008 | - | - | - |
| LVMI | 1.01 | 1.00–1.02 | 0.010 | - | - | - |
| LA volume | 1.07 | 1.03–1.12 | <0.001 | - | - | - |
| Diastolic dysfunction II-III | 3.30 | 1.60–6.83 | 0.001 | - | - | - |
| In the HFmrEF population | ||||||
| Male gender | 6.60 | 2.01–21.44 | 0.002 | - | - | - |
| LA volume | 1.10 | 1.01–1.20 | 0.020 | - | - | - |
| sPAP | 1.12 | 1.01–1.23 | 0.030 | - | - | − |
| In the HFpEF population | ||||||
| Age | 1.07 | 1.00–1.14 | 0.040 | - | - | - |
| NT-proBNP | 1.70 | 1.12–2.58 | 0.010 | - | - | - |
| Norepinephrine | 4.84 | 1.31–17.83 | 0.020 | - | - | - |
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate (with the Modification of Diet in Renal Disease-MDRD formula); Hb, hemoglobin; ICD, implantable cardioverter defibrillator; ICM, ischemic cardiomyopathy; LA, left atrium; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MR, mitral regurgitation; NT-proBNP, N-terminal fraction of pro–B-type natriuretic peptide; NYHA, New York Heart Association; OR, odds ratio; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.